Peptide vaccines for cancers expressing tumor-associated antigens

• US 9,067,973 B2
• Filed: 11/13/2013
• Issued: 06/30/2015
• Est. Priority Date: 02/21/2007
• Status: Active Grant

• Current Assignee: Oncotherapy Science, Inc.
• Original Assignee: Oncotherapy Science, Inc.
• Inventors: Tsunoda, Takuya, Ohsawa, Ryuji
• Primary Examiner(s): Huff, Sheela J
• Application Number:
  US14/079,144
• Publication Number:
  US 20140141027A1
• Time in Patent Office: 594 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001122 Ephrin Receptors [Eph]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 4/12 from animals; from humans
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value

Abstract

The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

Claims

1. An isolated peptide of less than about 15 amino acids having cytotoxic T cell inducibility, wherein the peptide is selected from the group consisting of:

(a) an isolated peptide comprising the amino acid sequences of SEQ ID NO;

114, 116, 117, or 121;

(b) an isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO;

114, 116, 117, or 121, wherein 1 or 2 several amino acids are substituted, deleted, or added.

2. The peptide of claim 1, wherein the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO:

114, 116, 117, or 121 is substituted with leucine or methionine.

3. The peptide of claim 1, wherein the C-terminal amino acid of the amino acid sequence of SEQ ID NO:

114, 116, 117, or 121 is substituted with valine or leucine.

4. The peptide of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO:

114, 116, 117, or 121.

5. A pharmaceutical composition comprising a peptide of claim 1 or a polynucleotide encoding the peptide, and a pharmaceutically acceptable carrier.

6. A method of inducing antigen-presenting cells having cytotoxic T cell inducibility, said method comprising the step of contacting an antigen-presenting cell with a peptide of claim 1.

7. A method of inducing a cytotoxic cell, said method comprising the step of:

(a) contacting an antigen-presenting cell with a peptide of claim 1,

(b) mixing the antigen-presenting cells of step (a) with a CD8+ T cell and co-culturing.

8. A composition for inducing an immune response against cells expressing the gene of SEQ ID NO:

7 wherein the composition comprises a peptide of claim 1 as the active ingredient and a pharmaceutically acceptable carrier.

9. The composition of claim 8, wherein the cells expressing the gene of SEQ ID NO:

7 are cancer cells.

10. The composition of claim 9, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

11. The composition of claim 8, formulated for administration to a subject whose HLA antigen is HLA-A2.

12. A method of inducing an immune response against cells expressing the gene of SEQ ID NO:

7 in a subject, said method comprising administering to said subject a composition comprising a peptide of claim 1, or a polynucleotide encoding said peptide.

13. The method of claim 12, wherein the cells expressing the gene of SEQ ID NO:

7 are cancer cells.

14. A method of claim 13, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

15. The composition of claim 5, wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterilized water, physiological saline, and phosphate buffer.

16. The composition of claim 8, wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterilized water, physiological saline, and phosphate buffer.

17. The method of claim 12, wherein the composition is administered in combination with an adjuvant.